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1. Introduction 
Pancreatic cancer is one of the most lethal malignant diseases with the worst prognosis. It is 
ranked as the fourth leading cause of cancer-related deaths in the United States. An 
unknown but important proportion of cancers develop in people who carry mutation in a 
cancer-predisposing gene. Identification of cancer-predisposing genetic mutations in 
susceptible individuals affords the opportunity to practise preventive medicine. Pancreatic 
cancer is an aetiologically complex disease whose development is contingent on the 
independent and joint effects of genes and environment. (Greer &Whitcomb, 2007). Recent 
analysis of human pancreas genomes showed that 12 common signaling pathways involved 
in cellular repair mechanisms, metabolism, cell-cycle regulation, genomic repair, and 
metastasis are affected in over two thirds of the pancreatic cancer genome, including mainly 
point mutations(Jones et al., 2008). 
Many risk factors have been associated with PC such as genetic factors and premalignant 
lesions, predisposing diseases and exogen factors. Genetic susceptibility, observed in 10% of 
cases includes inherited pancreatic cancer syndromes and familial cancers. However, the 
rest of 90% of pancreatic cancer recognise as risk factors a mix between genetic factors and 
environmental factors, too, but the exact etiopathogenesis remains unknown. 
2. Hereditary pancreatic cancer syndromes 
2.1 Hereditary breast ovarian cancer syndrome 
Hereditary breast ovarian cancer syndrome is associated with germ line mutation in the 
BRCA 2 and BRCA 1 gene and it is associated with a 7% lifetime risk in pancreatic cancer at 
70 years old. BRCA1 and 2 are tumour suppressor genes that are inherited in an autosomal 
dominant fashion with incomplete penetrance. They controls cell growth and differentiation 
and their loss drives tumorigenesis by involving in transcriptional regulation of gene 
expression and reairing of damaged DNA. The 6174delT mutation of BRCA2, occur ten 
times more frequently in Ashkenazi Jewish population and it is responsible for breast and 
ovarian familial cancer. BRCA2 mutations are found in as many as 12 to 17 percent of 
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patients with familial pancreatic cancer. Single nucleotide polymorphism of BRCA 1 and 2 
does not influence the risk for pancreatic cancer in sporadic pancreatic adenocarcinoma 
(McWilliams et al., 2009). For BRCA1 carriers, this relative risk is estimated to be 2-fold 
higher (Thomson et al., 2002) and for BRCA2 carriers, this relative risk is approximately 3-to 
4-fold higher (The Breast Cancer Linkage Consortium, 1999). Within 24/219 BRCA1 and 
17/156 BRCA2 families (representing 11% of overall individuals included in the study) there 
was at least 1 individual with pancreatic cancer. The onset of cancer was earlier than in 
general population : 59 in males and 69 in females in BRCA1families and 67 in males and 59 
in females in BRCA2 families (Kim et al., 2009). Compared to SEER data which showed a 
0.96:1 male:female ratio occurence of pancreatic cancer in general population, in BRCA1 
families, showed a 2:1 male: female ratio, possible linked to the competing mortality for 
breast and ovarian cancer in their female relatives (Kim et al., 2009). For these reasons, males 
under 65 years old in families with a strong history of breast, ovarian, and pancreatic cancer 
be considered for BRCA1/2 testing along with their female relatives. Cigarette smoking and 
exposure to oestrogen influences pancreatic cancer risk, but in a direction opposite to that of 
breast cancer risk in BRCA1/2 mutation carriers (Greer & Whitcomb, 2007). 
2.2 The Peutz-Jeghers syndrome 
The Peutz-Jeghers syndrome is an autosomally dominant hereditary disease with 
characteristic of hamartoma polyps of the gastrointestinal tract, and mucocutaneous 
melanin pigmentation. Almost half of these patients are carriers of a germinal serine-
treonine kinase 11STK11/LKB1 gene mutation (Giardiello et al., 2000). Wild-type 
STK11/LKB1 activates adenine monophosphate–activated protein kinase, which is a 
regulator of cellular energy metabolism. Activation of adenine monophosphate–activated 
protein kinase leads to inhibition of the mammalian target of rapamycin 1 (mTOR1), a 
serine/threonine kinase with a key position in the regulation of cell growth. The risk of PC 
is 132 times higher than for the general population (lifetime risk for cancer is 11-36%).  
2.3 Familial atypical multiple mole melanoma syndrome (FAMMM) 
Familial atypical multiple mole melanoma syndrome (FAMMM) is an autosomal dominant 
syndrome caused by a germline mutation in CDKN2A (or p16) gene on chromosome 9p21 
or in a minority of cases in the CDK4 gene on chromosome 12 (Goldstein et al., 2000; 
Wheelan et al., 1995). This syndrome is characterized by multiple nevi, multiple atypical 
nevi, and an increased risk of melanoma. The relative risk of developing pancreatic cancer is 
20 to 47 and the lifetime risk for pancreatic cancer is 16%(Vasen et al., 2000, De Snoo et al., 
2008). Among cases who reported having a first-degree relative with pancreatic cancer or 
melanoma, the carrier proportions were 3.3 and 5.3%, respectively. Penetrance for mutation 
carriers by age 80 was calculated to be 58% for pancreatic cancer and the risk of pancreatic 
cancer in smokers was 25 compared to non-carriers (McWilliams et al., 2011). The onset of 
pancreatis cancer in a historical cohort of 36 patients from 26 families with FAMM was 65 
years old. In a follow-up study group of 77 carriers of p16 mutation, 7 individuals 
developed a pancreatic cancer within 4 years and only 5 had curative resection, confirming 
rapidly growing tumor that could originate from small PanIN lesions in p16 mutation 
carriers(Vasen et al., 2010). 
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2.4 Lynch syndrome 
Lynch syndrome is an autosomal dominant condition caused by defects in mismatch repair 
genes (MLH1, MSH2, MSH6 or PMS2). It has recently been shown that in addition to 
colorectal and endometrial cancers these individuals have a 9-fold increased risk of 
developing pancreatic cancer compared with general population(Kastrinos et al., 2009). 
2.5 Hereditary pancreatitis 
Hereditary pancreatitis is a rare autosomal dominant disorder, in more than two-thirds of 
cases caused by a mutation in the SPINK1 and PRSS1 genes, with a high risk of pancreatic 
cancer. For this population, the cumulative risks of pancreatic cancer at the age of 50 and 75 
years are 11% and 49% for men and 8% and 55% for women, respectively(Rebours et al., 
2008). The risk was higher for smokers and for those with diabetes mellitus. 
2.6 Ataxia-teleangiectasia  
Ataxia-teleangiectasia with mutation of ATM gene on chromosome 17p is associated with 
pancreatic cancer , but the relative risk is unknown yet. 
3. Familial pancreatic cancer  
It may be considered in families with at least two first-degree relatives suffering from the 
disease, thus suggesting an autosomal dominant penetrance (Greenhalf et al., 2009). 
Families with only one relative with pancreatic cancer or with multiple pancreatic cancers in 
more distant relatives are considered as sporadic PC. The lifetime risk increases with the 
number of relatives involved. Individuals with two first-degree relatives with pancreatic 
cancer have a 6-fold increased risk of developing pancreatic cancer, and individuals with 
three or more first-degree relatives with pancreatic cancer have a 14 to 32-fold increased risk 
(Klein et al., 2004) . The risk of pancreatic cancer was similar in familial PC kindred 
compared to sporadic pancreatic cancer kindred members. Analysing more than 9000 
subjects, the presence of a young-onset pancreatic cancer patient, under 50 years old did not 
influence the risk of having pancreatic cancer inside familial PC kindred, but it added risk 
compared to sporadic pancreatic cancer (Brune et al., 2010). Smoking is a strong risk factor 
in familial pancreatic cancer kindred, particularly in males and people younger than 50 
years of age, as it increases the risk of pancreatic cancer by 2 to 3.7 times over the inherited 
predisposition and lowers the age of onset by 10 years (Rulyak et al., 2003).  
The genetic basis is not known, the BRCA2, palladin gene and PALB2 could play some role 
(Murphy et al., 2002; Couch et al., 2007; Pogue-Geile et al.,2006; Jones et al.,2009). The PALB2 
gene codes for a protein that binds to the BRCA2 protein and helps to localize BRCA2. 
(Tischkowitz et al.,2009, Jones et al.,2009). Palladin is a cytoskeleton-associated scaffold 
protein, with role in the formation of a desmoplastic tumor microenvironment (Giocoechea 
et al., 2010), but recent studies denied its involvement in carcinogenesis (Klein et al.,2009, 
Slater et al.,2007) 
There has been developed and validated a risk prediction model PancPRO based on age, 
pancreatic cancer status, age of onset, and relationship for all biological relatives (Wang et 
al., 2007). 
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Even genetic testing may be of benefit to many families, more than 80% of the clustering of 
pancreatic cancer in families remains unknown or the known mutation are not found. 
Mutations in the BRCA2gene account about 11% of families, PALB2 1–3% and the remaining 
genes account for <1% of familial pancreatic cancer. Genetic susceptibility for developing 
pancreatic cancer has been recently atributed to a single nucleotide polymorphism of gene 
located on 13q22.1 chromosome, considered as specific for pancreatic cancer, or of a gene 
located on 1p32.1 chromosome, which interact with betacatenin pathway(Petersen et al., 
2010). 
3.1 Genetic predisposition: ABO blood group  
Compared with blood group O, individuals with non-O blood group (type A, AB, or B) 
were significantly more likely to develop pancreatic cancer (adjusted hazard ratio for 
incident pancreatic cancer 1.32, 1.51. and 1.72, respectively)(Wolpin et al., 2009, Risch et al., 
2010), probably based on genetic variants in ABO locus 9q34 (Amundadottir et al, 2009). 
Another extended study identified susceptibility loci on 3 chromosomes- 13q22.1, 1q32.1 
and 5q15.33, the most specific being considered 13q22.1(Petersen et al., 2010). The incidence 
rates for pancreatic cancer (cases per 100,000 persons at risk) among White participants with 
blood types O, A, AB, and B were 28.9, 39.9, 41.8, and 44.5, respectively. In combination with 
smoking, overweight or diabetes, the non-O blood type was associated with ORs of 2.68, 
1.66, and 2.29, respectively, compared to subjects who had O blood type and lacked the 
exposure(Wolpin et al., 2010). The mechanism of influence of blood group antigens on risk 
for pancreatic cancer might be the alteration of the systemic inflammatory state (Wolpin et 
al., 2010). 
4. Premalignant lesions 
There are three known precursor lesions to pancreatic cancer: intraductal papillary 
mucinous neoplasm (IPMN), mucinous cystic neoplasia (MCN) and pancreatic intra-
epithelial neoplasia (PanIN). PanIN is by far the most common lesion and three grades of 
PanIN have been described as cellular atypia progresses from low grade dysplasia (PanIN 1) 
to high grade dysplasia (PanIN3), similar to colorectal cancer carcinogenesis. The 5-year-risk 
of PC is about 50% for MCN, 50% for main ductal IPMN while only 15% for branch IPMN. 
5. Predisposing diseases 
5.1 Chronic pancreatitis 
The risk of developing pancreatic cancer is about 5%(Raimondi et al., 2010), probably due to 
PanIN lesions or chronic inflammation. In a large multicentric study, the total risk reached 
1.8 percent at 10 years and 4 percent at 20 years, independently of the type of 
pancreatitis(Lowenfels et al., 1993; Howes et al., 2004). There is no need for systematic 
screening in patients with chronic pancreatitis, but acute onset of pain after long free-pain 
interval, a non-equilibrated diabetes without explanation, the onset of jaundice or weight 
loss require looking for pancreatic cancer. The risk is higher for non-alcoholic pancreatitis, 
as hereditary pancreatitis linked to PRSS1 mutations (40% at 70 years old) or tropical 
pancreatitis, form of hereditary pancreatitis linked to SPINK1 mutation (a 100 times higher 
risk than for the general population)(Lowenfels et al., 1993).  
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5.2 Diabetes mellitus 
Diabetes is associated with pancreatic cancer in about 40 to 60% of patients at the onset of 
symptoms, being a consequence or the cause of the disease. A meta-analysis of 20 studies 
(predominantly of patients with type 2 diabetes) estimated that the pooled relative risk for 
pancreatic compared to patients without diabetes was 2.1, especially among patients with 
long-standing diabetes(Everhart&Wright, 1995; Huxley et al., 2005).Diabetes associated with 
pancreatic cancer is often new-onset (<2-year duration), it resolves following cancer 
resection and appears to be associated with conventional risk factors for diabetes such as 
age, obesity and familial history (Pannala et al., 2008; Gupta et al., 2006). Even in the absence 
of frank diabetes mellitus, abnormal glucose metabolism and insulin resistance have been 
associated with pancreatic cancer(Stolzenberg-Solomon et al., 2005; Gapstur et al.,2000), and 
the insulin-growth factor(IGF) involvement might be the pathway in the pathogenesis. 
Although not all studies found an association between the risk of pancreatic cancer and the 
level of IGF, it seems that the polymorphism of IGF is associated with lower susceptibility to 
pancreatic cancer(Lin et al., 2004; Wolpin et al., 2007; Suzuki et al., 2008).The risk is higher in 
insulin ever users compared with nonusers (OR = 2.2, 95% CI = 1.6-3.7) and was restricted to 
insulin use of ≤3 years (OR = 2.4), but decreases after ten years of insulin use(Li et al., 2011). 
The explanation might be that the two diseases could share genetic risk factors in common. 
The CT screening is recommended for older patients with new-onset diabetes, especially 
those with family history or symptoms, as shown in a recent description of French families. 
5.3 Postgastrectomy or postcolecystectomy status 
Postgastrectomy or postcolecystectomy status were associated with an increased risk of 
pancreatic cancer, probably due to high level of circulating colecystokinin(Smith et al., 1990). 
5.4 Helicobacter pylori and hepatitis B  
Helicobacter pylori and hepatitis B have been found as associated factors to pancreatic 
cancer. The pathway may be represented by the polymorphism of genes involved in the 
inflammatory response, but further studies are needed for confirmation.  
6. Environmental factors 
6.1 Smoking 
The risk for pancreatic cancer is 1.5-2.5, higher with the numbers of cigarettes and in 
glutathione-S-transferase deficient persons and decreases 10 years after the smoking 
cessation. (Iodice et al, 2008). It increases the risk in hereditary chronic pancreatitis. 
Mutations in carcinogen-metabolizing genes, such as glutathione-S-transferase, N-acetyl-
transferase, cytochrome P450 and DNA-repair genes in oxidative metabolism(XRCC1, 
OGG1) with multiple sequence variants may be genetic modifiers for smoking-related 
pancreatic cancer (Duell et al., 2002; Li et al., 2006). In a recent case-control publication, the 
risk more than 15 years after smoking cessation was similar to that for never smokers. Also, 
there was a more significant risk for total exposure delivered at lower intensity for longer 
duration than for higher intensityfor shorter duration. These findings and the decline in risk 
after smoking cessation suggested that smoking has a latestage role in carcinogenesis. 
(Lynch et al., 2009). There is a synergistic interaction with diabetes mellitus and family 
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history of pancreatic cancer (Hassan et al.,2007). Smoking can be reponsible for familial 
agregation of pancreatic cancer individuals with lung and larynx cancer (Hiripi et al., 2009). 
6.2 Obesity  
A body mass index of at least 30 kg/m2 was associated with a significantly increased risk of 
pancreatic cancer compared with a BMI of less than 23 kg/m2 (relative risk 1.72), but an 
inverse relationship was observed for moderate physical activity when comparing the 
highest versus the lowest categories (relative risk 0.45) (Michaud et al., 2001). Centralized fat 
distribution may increase pancreatic cancer risk,especially in women, (Arslan et al., 2010). 
There have recently been discovered genetic factors which can reduce the risk of PC (PPARγ 
P12A GG genotype, NR5A2 variants) or which can enhance th risk in overweight patients 
(FTO, ADIPOQ) (Tang et al., 2011). Others have suggested that overweight and obese 
individuals develop pancreatic cancer at a younger age than do patients with a normal 
weight, and that they also have lower rates and duration of survival once pancreatic cancer 
is diagnosed (Li et al., 2009). Obesity in early adulthood was a risk factor for pancreatic 
cancer (Genkinger et al., 2010). 
6.3 The diet 
The diet based on fat and meat has been linked to the development of pancreatic cancer in 
many (Nothlings et al., 2005; Thiebaut et al., 2009), but not all studies (Michaud et al,2003, 
2005). The consumption of fresh fruits and vegetables were not associated with pancreatic 
cancer risk (Coughlin et al.,2000). Lower serum levels of lycopene and selenium have been 
found in subjects who subsequently developed pancreatic cancer (Burney et al.,1989). 
Although the majority of prospective cohort studies found no significant increase in the risk 
of pancreatic cancer with moderate to high levels of alcohol intake in a general population., 
a recent study has shown that a certain polymorphism of genes involved in the production 
and/or oxidation of acetaldehyde is associated with an increasing risk in developping 
pancreatic cancer (Michaud, 2004;Kanda et al., 2008). Folate deficiency, involved in DNA 
mutations and DNA methylation, may increase the risk of cancer. Although at least two 
variants of genes involved in folate metabolism were found to be associated to pancreatic 
cancer and smoking, these findings were not confirmed in all studies. Because the sample 
size was considered to be insufficient and the criteria for control selection of patients were 
different,these evidence were considered inadequately powered for drawing a conclusion. 
(Wang et al., 2005; Matsubayashi et al., 2005; Suzuki et al., 2008; Ohnami et al., 2008). No 
epidemiologic study has provided evidence to support the hypothesis that high glycemic 
index or glycemic load increases the risk of pancreatic cancer (Jiao L et al., 2009). 
Also, the role of TGF-beta pathway, proved to be linked to pancreatic cancer, and its genetic 
variants, but it still remains unclear. 
6.4 Exposure to sunlight 
Exposure to sunlight with increase of vitamin D synthesis might decrease the cancer risk and 
polymorphic variants in genes encoding the for synthesis enzyme is an important task for 
future research, as the role of melatonin receptor and genetic variants in clock genes. Based 
on different sun exposure in different geographic latitude, several studies sustained the 
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protective role of vitamin D against pancreatic cancer, in association with other factors as 
age and obesity (Grant, 2002, Guyton et al., 2003). The quantification of Vitamin D 
concentration must consider also the race (Afro-Americans has a higher risk for PC), the 
season of blood drawn and presence of supplemental in diet (Stolzenberg-Solomon, 2009). 
6.5 Alcohol consumption 
A recent study showed a moderate risk to heavy alcohol drinkers ( about 40 g alcohol daily) 
and liquor users ( relative risk 1.45-1.62) , probably due to their nitrosamine content (Jiao et 
al., 2009), sustained by other studies only in men (Hassan et al., 2007). 
6.6 Demographic factors 
Advanced age, between 60 and 80 is associated with 80% of pancreatic cancers. Other 
demographic factors that are associated with a modest (about 2-fold) increased risk include 
male gender, Jewish descent and black ethnicity(Lillemoe et al., 2000). 
Gene function  Gene 
symbol  
Gene full name  Gene 
location  
Concentration 
tumor vs 
normal  
Transcription  ZNF  zinc finger protein  19q13.31  3.38  
 MIXL1  Mix1 homeobox-like 1  1q42.12  6.24  
 SEPT1  Septin 1  16p11.1  3.42  
Intracellular 
signaling  
FLJ 
42953  
breakpoint cluster region 
pseudogene 2  
22q11.21  3.02  
 AGRP  agouti related protein 
homolog  
16q22   6.51  
Intracellular 
transport  
CCDC 
88  
coiled-coil domain containing 
88B  
11q12.3   4.61  
 UTP14
A  
U3 small nucleolar 
ribonucleoprotein  
Xq26.1   3.44  
 VPS11  vacuolar protein sorting 11 
homolog  
17p11.2  3.33  
 LLRC 
21  
leucine-rich repeat, 
immunoglobulin-like and 
transmembrane domains  
10q23  3.33  
 CHRM3  cholinergic receptor, 
muscarinic 3  
1q43  3.01  
Table 1. Genes with significant different expression (overexpressed or underexpressed) in 
pancreatic cancer compared to normal pancreatic tissue.  
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Our research on 16 tissue samples of T3 pancreatic cancer comparing to normal tissue in the 
same patients analysed by microarray showed that there were 41 overexpressed genes and 402 
underexpressed genes. From those with tumor concentration three times modified compared 
to normal tissue we noticed genes involved in transcription, intracellular signaling and 
intracellular transport (Table I), which need further validation on larger sample groups (data 
unpublished). This showed that genomic tissue microarray analysis represents a powerful 
strategy for identification of potential biomarkers in pancreatic cancer.  
7. Conclusions  
Pancreatic cancer is a pathological status with clear inheritance in only 10% of cases, the 
others seems to be linked to premalignant situations, other diseases or environmental factors 
in which genetic implications need further investigations. The gene-gene and gene- 
environment interactions have to be more extensively studied, especially because there are 
not only single-nuclear polymorphisms, but also DNA copy number variations and 
variable-number tandem repeats which can be linked to the risk of pancreatic cancer. 
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